---
source_url: https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/nausea_vomiting
content_type: therapeutic_choices
document_id: nausea_vomiting
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:41.178379Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: nausea_vomiting.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types therapeutic_choices
  note: Requires valid CPS access credentials
---

# Nausea and Vomiting

### Nausea and Vomiting

|  |
| --- |
| Christine Hughes, BScPharm, PharmDRae Petrucha, MD, CCFP |
| Date of Revision: June 2, 2023 |
| Peer Review Date: August 14, 2020 |


CPhA acknowledges the contribution of Dr. Cathy MacLean as a previous author of this content.

#### Introduction

Nausea is a symptom (not a diagnosis) that refers to the unpleasant sensation of the imminent need to vomit. Vomiting is the forceful expulsion of gastric contents with contraction of the abdominal and chest wall musculature. Nausea and vomiting may be transient symptoms secondary to a self-limited condition such as viral gastroenteritis or part of more complex medical issues. The underlying cause should be determined when possible. Approaches to treatment are dependent on the associated risk factors and diagnosis, which may include postoperative nausea and vomiting (PONV); chemotherapy-induced nausea and vomiting (CINV); opioid-induced nausea and vomiting (OINV); or metabolic, GI, vestibular or neurologic causes, such as motion sickness.â€‹[^[1]]

This chapter addresses the management of general nausea and vomiting. The management of cancer chemotherapy- or radiation-induced nausea and vomiting is addressed in Chemotherapy-Induced Nausea and Vomiting and Management of Side Effects of Cancer Therapy and Radiation Therapy. The management of nausea and vomiting of pregnancy is addressed in Nausea and Vomiting of Pregnancy.

Causes of nausea include:



Complications of prolonged or severe nausea and vomiting include esophageal rupture, Mallory-Weiss tears, dehydration, hypokalemia, hypomagnesemia, hypo- or hypernatremia, metabolic alkalosis, malnutrition, and dental caries.

#### Goals of Therapy



#### Investigations



#### Therapeutic Choices

#### Nonpharmacologic Choices



To prevent motion sickness, counsel patients to:â€‹[^[3]]



Acupressure wristbands (Sea-Bands) have not been shown to be beneficial for preventing motion sickness. In a controlled study of experimental motion sickness, neither acupressure nor acustimulation were of benefit;â€‹[^[4]] however, a systematic review found no difference between antiemetic drugs and stimulation of the PC6 acupoint on the wrist in preventing postoperative nausea and vomiting.â€‹[^[5]]

Aromatherapy with inhaled isopropyl alcohol pads (held 1â€“2 cm below the nostrils) has been shown to be more effective than placeboâ€‹[^[6]] or ondansetronâ€‹[^[7]] in reducing nausea symptoms within 30 minutes postintervention in adults in the emergency department.

Maintaining fluid intake helps prevent dehydration and electrolyte disturbances. The amount of fluid required depends on the amount lost through vomiting and/or diarrhea. Adults require 1â€“3 L of total water intake to maintain normal hydration status.â€‹[^[8]] In patients who are vomiting several times daily, additional fluid intake may be needed. For mild dehydration, drinking adequate amounts of water may be all that is required. To treat moderate to severe dehydration, it is necessary to replace electrolytes (especially sodium and potassium). Oral rehydration solutions with appropriate amounts of electrolytes are recommended under these circumstances.â€‹[^[9]]

#### Pharmacologic Choices

For comparative ingredients of nonprescription products, consult the *Compendium of Products for Minor Ailments*â€”Gastrointestinal Products: Antiemetics; Vitamin and Mineral Products: Single Entity.

Selected agents used in the management of nausea and vomiting are described in Table 1.â€‹[^[10]]â€‹[^[11]] For further discussion of pharmacologic therapy for nausea and vomiting, consult Chemotherapy-Induced Nausea and Vomiting and Nausea and Vomiting of Pregnancy.

When selecting a drug, consider whether the nausea is acute or chronic, review concurrent medications, and attempt to identify the underlying cause of nausea (see Figure 1). A preventive approach may be appropriate in certain situations, for example, in the management of motion sickness. Many patients cannot tolerate oral medications when nauseated, and alternative routes of administration (IM, IV, SC, rectal or transdermal) may be more suitable.

For treatment of nausea and vomiting associated with viral gastroenteritis, there is no evidence that one antiemetic is superior to another. The initial choice should be made on the basis of previous response, available routes of administration, cost, adverse effects and patient preference. These criteria often result in diphenhydramine or dimenhydrinate being tried first. Dimenhydrinate consists of 2 drugs (diphenhydramine and 8-chlorotheophylline) and must be metabolized to its active ingredient, diphenhydramine, resulting in a slower onset of action.â€‹[^[12]]

If symptoms are worsened by movement, it may be surmised that acetylcholine is a significant contributor, and anticholinergic agents such as first generation antihistamines, e.g., diphenhydramine, dimenhydrinate or hydroxyzine, may be tried first. If symptoms are associated with a feeling of fullness in the stomach, a prokinetic agent such as metoclopramide or domperidone may be a logical starting point. Caution is warranted with these agents since domperidone is associated with a small increased risk of serious ventricular arrhythmias or sudden cardiac deathâ€‹[^[13]] and metoclopramide is associated with extrapyramidal symptoms (even in children) and tardive dyskinesia (involuntary movements of the tongue, face, mouth or jaw). If patients fail to respond to these initial measures, base selection of other antiemetics on adverse effects, available routes of administration, patient preference and cost. Consider trying agents with different mechanisms of action if combinations of antiemetics are to be used.

#### Motion Sickness

Since acetylcholine and histamine are thought to be the most important neurotransmitters causing motion sickness, it follows that anticholinergic and antihistaminergic drugs are fairly effective in controlling it. Prevention is more effective than treatment in established nausea and vomiting.



#### Opioid-Induced Nausea and Vomiting

Therapeutic options for opioid-induced nausea and vomiting include the following:



#### Choices during Pregnancy and Breastfeeding

Since dimenhydrinate is recommended for augmenting pyridoxine treatment in pregnancyâ€‹[^[23]] and is considered generally safe in pregnancy, it can be considered for intermittent therapy of motion sickness in pregnant patients. Promethazine may also be used.â€‹[^[23]]

See Nausea and Vomiting of Pregnancy for therapeutic choices in pregnancy and breastfeeding. A discussion of general principles on the use of medications in these special populations can also be found in Drugs Use during Pregnancy and Drug Use during Breastfeeding; other specialized reference sources are provided in these appendices.

#### Therapeutic Tips



#### Algorithms

![](images/nauseavomitingpsc_asspatnauvom.gif)


**AI Image Description:**
This image is a flowchart for managing nausea and vomiting, detailing assessment and treatment strategies.

### Initial Assessment:
- **Thorough patient assessment:**
  - History: Evaluate onset, frequency, appearance of vomit, aggravating/remitting factors, severity, associated symptoms (fever, abdominal pain).
  - Physical examination.
  - Additional investigations as needed (e.g., pregnancy test).

### Non-Pharmacologic Measures:
- **Patient education:**
  - Ensure adequate oral hydration.
  - Eat smaller, more frequent meals.
  - Avoid smells or foods that worsen symptoms.
  - Practice relaxation therapy, etc.

### Treatment Strategy:
1. **Identify and eliminate underlying cause, if possible.**
2. **Tailor pharmacologic treatment to the most likely underlying cause.**

### Specific Conditions and Treatments:
- **Viral Gastroenteritis:**
  - Antihistamines (e.g., dimenhydrinate).
  - Dopamine antagonists (e.g., metoclopramide, prochlorperazine).

- **Motion Sickness:**
  - Review non-pharmacologic measures (e.g., avoid large meals within 3 hours of travel; avoid smoking, alcohol, disagreeable odors, visual stimuli).
  - Antihistamines (e.g., dimenhydrinate, diphenhydramine).
  - Anticholinergics (e.g., scopolamine patch).

- **Drug-Induced (e.g., opioids):**
  - Explore options like altering administration schedule, reducing dose, using alternate agents, or discontinuing if appropriate.
  - Antihistamines (e.g., dimenhydrinate).
  - Dopamine antagonists (e.g., domperidone, metoclopramide, prochlorperazine).
  - Serotonin 5-HTâ‚ƒ receptor antagonists (e.g., ondansetron).

### If Treatment is Ineffective:
- Combine 2 or more antiemetics from different pharmacologic classes (e.g., antihistamines, anticholinergics, dopamine antagonists, serotonin antagonists).

This flowchart provides a structured approach to assessing and managing nausea and vomiting, emphasizing both non-pharmacologic and pharmacologic interventions tailored to specific causes.

*AI-generated description for accessibility and content understanding*


#### Drug Table


**Drug Class: Anticholinergics**


**Drug Class: Antihistamines**


**Drug Class: Dopamine Antagonists**


**Drug Class: Natural Health Products**


**Drug Class: Serotonin 5-HT3 Receptor Antagonists**

| Drug/â€‹Cost[a] | Dosage | Adverse Effects | Drug Interactions |
| --- | --- | --- | --- |
| **scopolamine** (Transderm) | 1.5 mg (1 transdermal patch) Q72H PRN Caution in the elderly Should not be used in children | Sedation, constipation, dry mouth, blurred vision, rash, allergic contact dermatitis, eye irritation if hands touch eyes after handling patch. Disorientation, delirium. The elderly are at increased risk of CNS effects. | Additive sedation with alcohol or other sedating medications. |
| **dimenhydrinate** (Gravol, generics) | Immediate-release formulations: Adults:25â€“100 mg Q4â€“6H PRN PO/PR/IM/IV (maximum 400 mg/day)Children 6â€“12 y: 25â€“50 mg Q6â€“8H PRN POChildren 2â€“6 y: 15â€“25 mg Q6â€“8H PRN POLong-acting formulation: Adults: 100 mg Q8â€“12H PRN PO (maximum 300 mg/day) | Sedation, anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), confusion. The elderly may be particularly susceptible.Paradoxical excitation in children. | Additive sedation with alcohol or other sedating medications. |
| **diphenhydramine** (Benadryl, generics) | Adults: 25â€“50 mg TIDâ€“QID PRN PO (maximum 200 mg/day)10â€“50 mg TIDâ€“QID PRN IM/IVChildren 6â€“12 y: 12.5â€“25 mg Q4â€“6H PRN PO | Sedation, anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), confusion. The elderly may be particularly susceptible. | Additive sedation with alcohol or other sedating medications.Inhibits CYP2D6 and can increase serum levels of many drugs including antidepressants and cardiovascular drugs. |
| **hydroxyzine** (Atarax, generics) | Initial dose: 25â€“100 mg PO/IM; adjust subsequent doses based upon response; may administer Q4â€“6H PRN PO/IM (maximum 100 mg/day due to risk of QTc prolongation)Not recommended in pregnancy | Sedation, anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), confusion. The elderly may be particularly susceptible. | Additive sedation with alcohol or other sedating medications. |
| **promethazine** (Histantil) | 12.5â€“25 mg Q4â€“6H PRN PO | Sedation, anticholinergic effects, EPS. | Additive sedation with alcohol or other sedating medications. |
| **domperidone** (generics) | 10 mg TID PO (maximum 30 mg/day) | Diarrhea, abdominal cramps and distention, headache, hyperprolactinemia, QTc prolongation. | Additive sedation with alcohol or other CNS depressants. Metabolized by CYP3A4; may be affected by CYP3A4 inhibitors or inducers. |
| **haloperidol** (generics) | 0.5â€“2 mg Q12H PRN PO/IM/IV | QTc prolongation. | Additive sedation with alcohol or other CNS depressants. Caution if used with other drugs that prolong the QTc interval. |
| **metoclopramide** (Metonia, other generics) | 10â€“20 mg TIDâ€“QID PRN PO/SC/IV | Diarrhea, abdominal cramps and distention, headache, hyperprolactinemia, drowsiness, fatigue, EPS. | Additive sedation with alcohol or other sedating medications. |
| **prochlorperazine** (generics) | 5â€“10 mg TIDâ€“QID PRN PO/PR | Sedation, anticholinergic effects, EPS. | Additive sedation with alcohol or other sedating medications. |
| **ginger (zingiber officinale)** (Gravol Natural Source, others) | 250 mg QID or 500 mg BID PO | Abdominal discomfort, diarrhea, heartburn, pepper-like irritant effect in the mouth and throat. | May inhibit in vitro CYP2C19; clinical significance unknown. |
| **ondansetron** (Zofran, Zofran, Ondansetron, other generics) | PO: 16â€“24 mg/day divided Q6â€“8HIV: up to 16 mg initially infused over no less than 15 min (do not exceed 8 mg if â‰¥75 y). Subsequent IV doses must not exceed 8 mg/dose and may be given 4H and 8H after initial dose | Headache, constipation, diarrhea, sedation, bradycardia, dizziness. Transient ECG changes, QTc prolongation. | May decrease analgesic effect of tramadol. CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) decrease ondansetronâ€™s blood concentrations. Caution if used with other drugs that prolong the QTc interval. |


**ðŸ«˜ Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI description pending for: images/kidney.gif -->

central nervous system

electrocardiogram

extrapyramidal symptoms

#### Suggested Readings

Anderson WD, Strayer SM. Evaluation of nausea and vomiting: a case-based approach. *Am Fam Physician* 2013;88(6):371-9.

Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. *Cochrane Database Syst Rev* 2015;(9):CD010106.

Hendren G, Aponte-Feliciano A, Kovac A. Safety and efficacy of commonly used antiemetics. *Expert Opin Drug Metab Toxicol* 2015;11(11):1753-67.

Kaye AD, Cornett EM, Chalabi J et al. Pharmacology of antiemetics: update and current considerations in anesthesia practice. *Anesthesiol Clin* 2017;35(2):e41-e54.

Lacy BE, Parkman HP, Camilleri M. Chronic nausea and vomiting: evaluation and treatment. *Am J Gastroenterol* 2018;113(5):647-59.

Murdin L, Golding J, Bronstein A. Managing motion sickness. *BMJ* 2011;343:d7430.

Smith HS, Laufer A. Opioid induced nausea and vomiting. *Eur J Pharmacol* 2014;722:67-78.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/nausea_vomiting](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/nausea_vomiting)  
**Content Type:** therapeutic_choices  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *nausea_vomiting*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/nausea_vomiting


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 â€¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/CHAPTER/en/nausea_vomiting)*
